Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BJDX NASDAQ:CODX NASDAQ:FEMY NASDAQ:HIND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$4.89+3.2%$2.42$1.62▼$16.68$4.90M0.824.02 million shs62,860 shsCODXCo-Diagnostics$4.29-8.7%$3.12$1.26▼$46.50$17.32M2.7416.52 million shs434,068 shsFEMYFemasys$4.18-12.6%$7.69$4.02▼$22.20$14.43M-2.23123,734 shs89,814 shsHINDVyome$2.30+0.9%$2.17$1.75▼$18.60$16M1.4823,992 shs8,347 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+5.57%-10.57%+164.80%+149.47%-34.17%CODXCo-Diagnostics-3.69%-18.40%+173.26%+67.86%-46.89%FEMYFemasys+1.06%-33.09%-36.62%-58.07%-71.88%HINDVyome+5.07%-0.87%+15.15%+1.33%+227,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBJDXBluejay Diagnostics$4.89+3.2%$2.42$1.62▼$16.68$4.90M0.824.02 million shs62,860 shsCODXCo-Diagnostics$4.29-8.7%$3.12$1.26▼$46.50$17.32M2.7416.52 million shs434,068 shsFEMYFemasys$4.18-12.6%$7.69$4.02▼$22.20$14.43M-2.23123,734 shs89,814 shsHINDVyome$2.30+0.9%$2.17$1.75▼$18.60$16M1.4823,992 shs8,347 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBJDXBluejay Diagnostics+5.57%-10.57%+164.80%+149.47%-34.17%CODXCo-Diagnostics-3.69%-18.40%+173.26%+67.86%-46.89%FEMYFemasys+1.06%-33.09%-36.62%-58.07%-71.88%HINDVyome+5.07%-0.87%+15.15%+1.33%+227,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBJDXBluejay Diagnostics 1.00SellN/AN/ACODXCo-Diagnostics 2.00Hold$67.501,473.43% UpsideFEMYFemasys 2.50Moderate Buy$106.672,451.83% UpsideHINDVyome 2.40Hold$15.00552.17% UpsideCurrent Analyst Ratings BreakdownLatest BJDX, CODX, FEMY, and HIND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/26/2026CODXCo-Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/6/2026HINDVyome Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold5/4/2026HINDVyome Litchfield Hills ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026HINDVyome Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)3/27/2026BJDXBluejay Diagnostics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBJDXBluejay DiagnosticsN/AN/AN/AN/A$8.43 per shareN/ACODXCo-Diagnostics$620K25.53N/AN/A$9.14 per share0.47FEMYFemasys$2.29M5.51N/AN/A$2.01 per share2.08HINDVyome$320K50.46N/AN/A$0.67 per share3.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBJDXBluejay Diagnostics-$6.85M-$11.63N/AN/AN/AN/A-144.27%-115.00%8/19/2026 (Estimated)CODXCo-Diagnostics-$46.90M-$15.77N/AN/AN/A-6,760.63%-164.92%-141.15%8/14/2026 (Estimated)FEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)HINDVyome-$10.26M-$12.27N/AN/AN/A-270.58%-203.92%-134.16%N/ALatest BJDX, CODX, FEMY, and HIND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CODXCo-Diagnostics-$3.75-$4.06-$0.31-$4.06$0.13 million$0.15 million5/12/2026Q1 2026HINDVyomeN/A-$0.15N/A-$0.15N/A$0.03 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 million5/7/2026Q1 2026BJDXBluejay DiagnosticsN/A-$1.95N/A-$1.95N/AN/A3/31/2026Q4 2025CODXCo-Diagnostics-$3.90-$16.65-$12.75-$16.65$0.13 million$0.26 million3/31/2026Q4 2025FEMYFemasys-$1.6666-$0.20+$1.4666-$0.01$1.06 million$0.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBJDXBluejay DiagnosticsN/AN/AN/AN/AN/ACODXCo-DiagnosticsN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AHINDVyomeN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBJDXBluejay DiagnosticsN/A2.812.81CODXCo-DiagnosticsN/A2.282.09FEMYFemasys0.533.911.98HINDVyomeN/A4.274.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBJDXBluejay Diagnostics18.47%CODXCo-Diagnostics14.99%FEMYFemasys65.27%HINDVyome22.06%Insider OwnershipCompanyInsider OwnershipBJDXBluejay Diagnostics0.08%CODXCo-Diagnostics5.40%FEMYFemasys7.55%HINDVyome33.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBJDXBluejay Diagnostics91.03 million1.03 millionNot OptionableCODXCo-Diagnostics1003.69 million3.49 millionOptionableFEMYFemasys303.02 million2.79 millionNot OptionableHINDVyome507.02 million4.70 millionN/ABJDX, CODX, FEMY, and HIND HeadlinesRecent News About These CompaniesVyome Q1 Earnings Call HighlightsJune 6, 2026 | americanbankingnews.comVyome Holdings, Inc. (NASDAQ:HIND) Given Consensus Recommendation of "Hold" by BrokeragesJune 3, 2026 | americanbankingnews.comVyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance SheetMay 28, 2026 | businesswire.comVyome Holdings (HIND) price target decreased by 23.33% to 11.73May 15, 2026 | msn.comTata-backed Impetis licenses JAK inhibitor assets to Vyome HoldingsMay 13, 2026 | business-standard.comBVyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market OpportunityMay 13, 2026 | pharmiweb.comPVyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026April 22, 2026 | bakersfield.comBVyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026April 6, 2026 | businesswire.comVyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...March 30, 2026 | uk.finance.yahoo.comVyome Reports Transformational 2025 Results: Company Well Positioned for Breakout PhaseMarch 26, 2026 | finance.yahoo.comLivechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics CompanyFebruary 24, 2026 | finance.yahoo.comVyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 MonthsFebruary 11, 2026 | finance.yahoo.comVyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 ResultsFebruary 2, 2026 | businesswire.comVyome stock soars after analyst values lead drug candidate at $1 billionJanuary 27, 2026 | in.investing.comIndependent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 StudyJanuary 27, 2026 | finance.yahoo.comWe're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn RateDecember 29, 2025 | finance.yahoo.comVyome’s LiveChain Signs LOI for Humanyze Note AcquisitionDecember 23, 2025 | tipranks.comVyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated CompanyDecember 22, 2025 | finance.yahoo.comVyome stock soars after malodor treatment shows positive resultsDecember 8, 2025 | investing.comVyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA ApprovalDecember 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Is Co-Diagnostics National Security’s Next Diagnostic Pick?By Jeffrey Neal Johnson | May 28, 2026BJDX, CODX, FEMY, and HIND Company DescriptionsBluejay Diagnostics NASDAQ:BJDX$4.89 +0.15 (+3.16%) Closing price 04:00 PM EasternExtended Trading$4.77 -0.12 (-2.45%) As of 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.Co-Diagnostics NASDAQ:CODX$4.29 -0.41 (-8.72%) Closing price 04:00 PM EasternExtended Trading$4.14 -0.16 (-3.61%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Femasys NASDAQ:FEMY$4.18 -0.60 (-12.55%) Closing price 04:00 PM EasternExtended Trading$4.38 +0.20 (+4.67%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Vyome NASDAQ:HIND$2.30 +0.02 (+0.88%) Closing price 04:00 PM EasternExtended Trading$2.30 0.00 (0.00%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
